Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.

Huang YY, Yu YF, Zhang C, Chen Y, Zhou Q, Li Z, Zhou S, Li Z, Guo L, Wu D, Wu Y, Luo HB.

J Med Chem. 2019 Apr 11;62(7):3707-3721. doi: 10.1021/acs.jmedchem.9b00224. Epub 2019 Mar 29.

PMID:
30888810
2.

Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.

Li QY, Xu MK, Liu G, Christoffersen CT, Wang MW.

Acta Pharmacol Sin. 2013 Aug;34(8):1116-20. doi: 10.1038/aps.2013.25. Epub 2013 Apr 22.

3.

Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.

Andrés JI, Buijnsters P, De Angelis M, Langlois X, Rombouts F, Trabanco AA, Vanhoof G.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):785-90. doi: 10.1016/j.bmcl.2012.11.077. Epub 2012 Dec 1.

PMID:
23260348
4.

Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.

Zagorska A, Partyka A, Bucki A, Gawalskax A, Czopek A, Pawlowski M.

Curr Med Chem. 2018;25(29):3455-3481. doi: 10.2174/0929867325666180309110629. Review.

PMID:
29521210
5.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
6.

β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.

Lee K, Lindsey AS, Li N, Gary B, Andrews J, Keeton AB, Piazza GA.

Oncotarget. 2016 Feb 2;7(5):5353-65. doi: 10.18632/oncotarget.6705.

7.

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Dai Z, Zhu MM, Peng Y, Machireddy N, Evans CE, Machado R, Zhang X, Zhao YY.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1423-1434. doi: 10.1164/rccm.201710-2079OC.

PMID:
29924941
8.

Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities.

Li J, Chen JY, Deng YL, Zhou Q, Wu Y, Wu D, Luo HB.

Front Chem. 2018 May 15;6:167. doi: 10.3389/fchem.2018.00167. eCollection 2018.

9.

Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.

Murray F, Maclean MR, Insel PA.

Handb Exp Pharmacol. 2011;(204):279-305. doi: 10.1007/978-3-642-17969-3_12. Review.

PMID:
21695645
10.

Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice.

De Franceschi L, Platt OS, Malpeli G, Janin A, Scarpa A, Leboeuf C, Beuzard Y, Payen E, Brugnara C.

FASEB J. 2008 Jun;22(6):1849-60. doi: 10.1096/fj.07-098921. Epub 2008 Feb 1.

PMID:
18245171
11.

Phosphodiesterase 5 inhibitors for pulmonary hypertension.

Barnes H, Brown Z, Burns A, Williams T.

Cochrane Database Syst Rev. 2019 Jan 31;1:CD012621. doi: 10.1002/14651858.CD012621.pub2.

PMID:
30701543
12.

PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.

Giralt A, Saavedra A, Carretón O, Arumí H, Tyebji S, Alberch J, Pérez-Navarro E.

Hippocampus. 2013 Aug;23(8):684-95. doi: 10.1002/hipo.22128. Epub 2013 Apr 29.

PMID:
23576401
13.

3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.

Lan TH, Chen XL, Wu YS, Qiu HL, Li JZ, Ruan XM, Xu DP, Lin DQ.

Eur J Pharmacol. 2018 Jun 15;829:102-111. doi: 10.1016/j.ejphar.2018.04.011. Epub 2018 Apr 14.

PMID:
29665366
14.
15.

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.

Cavasin MA, Demos-Davies KM, Schuetze KB, Blakeslee WW, Stratton MS, Tuder RM, McKinsey TA.

J Transl Med. 2014 Nov 26;12:314. doi: 10.1186/s12967-014-0314-y.

16.

Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.

Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Donti A, Branzi A, Picchio FM.

Drugs. 2008;68(8):1049-66. Review.

PMID:
18484798
17.

Targeted therapies in pulmonary arterial hypertension.

Montani D, Chaumais MC, Guignabert C, Günther S, Girerd B, Jaïs X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M.

Pharmacol Ther. 2014 Feb;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002. Epub 2013 Oct 14. Review.

18.

Endothelin receptor antagonists for pulmonary arterial hypertension.

Liu C, Chen J.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004434. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004434.

PMID:
16856046
19.

Pulmonary arterial hypertension: pathogenesis and clinical management.

Thenappan T, Ormiston ML, Ryan JJ, Archer SL.

BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492. Review.

PMID:
29540357
20.

Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.

Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F.

Circulation. 2007 May 1;115(17):2331-9. Epub 2007 Apr 16.

PMID:
17438150

Supplemental Content

Support Center